Honokiol Ameliorates Cerebral Infarction from Ischemia-Reperfusion Injury in Rats

Abstract

Honokiol, a constituent extracted from Magnolia officinalis, had been shown be an antioxidant and an anti-platelet agent in biological systems with an anti-arrhythmic effect and a myocardial protective effect on ischemia-reperfusion injury. We examined the neuroprotective effect of honokiol in rats subjected to focal cerebral ischemia. Honokiol was administered intravenously either at fifteen minutes before right middle cerebral artery occlusion (pretreatment groups) or when both common carotid arteries clips were removed (treatment groups). The results showed that there was no significant hemodynamic change after intravenous infusion of honokiol at the dosages of 10(-8), 10(-7) and 10(-6) g/kg in both groups. However, honokiol significantly reduced the total volume of infarction at the doses of 10(-7) or 10(-6) g/kg in both pretreatment and treatment groups. This study suggests that honokiol is a potent neuroprotective agent in focal cerebral ischemia. This beneficial effect may be related to its antioxidant effect and anti-platelet aggregation activity.

Taxifolin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation

“…The infarct volume induced by CI/R injury in this study (around 20% of the right brain hemisphere) was comparable with that of our previous reports [20,27]. Taxifolin (0.1-1.0 lg/kg) dosedependently ameliorated CI/R-induced brain infarction by 40-65% (Figure 1 upper panel, one-way ANOVA, p<0.05).…”

“…Twenty-four hours after the surgery, the rats were anesthetized and sacrificed. During the entire experiment, the blood gas data and physiological data were monitored as in our previous report [20]. The experimental grouping included one sham-operated group (sham, n=10), two (0.1 and 1.0 lg/kg) taxifolintreated groups (n=10, for each dose), and one CI/ R group (CI/R only, n=10).…”

Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of <i>Magnolia officinalis </i>

“…Honokiol has also been found to have a variety of pharmacological action, such as antiinfl ammatory action (22), antithrombotic activity (23), anti-arrhythmic activity (24), neuroprotective activity (15), antioxidative action (25), and anxiolytic action (26). Numerous animal studies have also demonstrated that honokiol acts as an anti-stress agent and a potent suppressor of oxidative damage and cancer (27).…”

Honokiol: A potent chemotherapy candidate for human colorectal carcinoma

“…It is widely used by Chinese people in treating thrombotic stroke, typhoid fever, anxiety and nervous disturbance [1] when used in combination with other herbs. With its major active constituent extracted from the bark of Houpu, honokiol has been found having a variety of pharmacological effects, such as anti-inflammatory [2] , antithrombotic [3] , anti-arrhythmic [4] , antioxidative [5] and anxiolytic effects [6] . Recently, honokiol has been reported to exhibit a potent cytotoxicity by inducing cell apoptosis in rat and human leukemia cells [7,8] , human fibrosarcoma cells [9] , human squamous lung cancer CH27 cells [10] and human SVR angiosarcoma cells [11] , yet there has been no report on honokiol in the treatment of human colorectal carcinoma.…”